HIGHLIGHTS
- What: This study examines the effectiveness and tolerability of eptinezumab in a real-world setting, with a particular focus on whether prior CGRP mAb therapy affects the response to therapy. The analysis showed that eptinezumab was still effective in individual cases even after three failed ptCGRP, although a placebo effect of the infusion cannot be assessed due to the real-life setting.
- Who: Armin Scheffler from the real‑world analysis from Germany have published the paper: Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.